1
|
Sorby DL, Tozer TN. On the Evaluation of Biologic Availability of Digoxin from Tablets. ACTA ACUST UNITED AC 2017. [DOI: 10.1177/106002807300700205] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Donald L. Sorby
- Department of Pharmacy, School of Pharmacy, University of California at San Francisco. faculty of the School of Pharmacy, University of Washington, Seattle, WA 98195
| | - Thomas N. Tozer
- Department of Pharmacy, School of Pharmacy, University of California at San Francisco. faculty of the School of Pharmacy, University of Washington, Seattle, WA 98195
| |
Collapse
|
2
|
|
3
|
Landmark Publication from The American Journal of the Medical Sciences: The Clinical Pharmacology of Digitalis Glycosides: A Review. Am J Med Sci 2010; 339:462-81. [DOI: 10.1097/maj.0b013e3181bd7b6b] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
4
|
|
5
|
Bertler A, Redfors A. Plasma levels of digoxin in relation to toxicity. ACTA PHARMACOLOGICA ET TOXICOLOGICA 2009; 29 Suppl 3:281-7. [PMID: 5316408 DOI: 10.1111/j.1600-0773.1971.tb03307.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
6
|
Abstract
The primary goal of therapy for metastatic breast cancer is to improve the outcome for patients. Ideally, this should be achieved with minimal short-term side effects and without long-term irreversible toxicity. Trastuzumab (Herceptin; F. Hoffmann-La Roche, Basel, Switzerland) is proven to be efficacious in women with metastatic breast cancer who have HER2-positive disease. Data from pivotal clinical trials and postmarketing surveillance in women with metastatic breast cancer confirm that trastuzumab is also well tolerated with a low incidence of conventional chemotherapeutic side effects. Severe adverse events are confined to serious infusion-related reactions and cardiac issues, which are infrequent and readily managed. Patients at risk of these severe events can be identified before starting trastuzumab therapy. Ideally, treatment should also be convenient for the patient. This can be achieved through less frequent dosing. A 3-weekly trastuzumab schedule, with higher individual loading and maintenance doses than the conventional weekly schedule, has been investigated. This has similar efficacy, tolerability, and pharmacokinetics (exposure) to the weekly regimen, providing a convenient schedule.
Collapse
|
7
|
Hui J, Geraets DR, Chandrasekaran A, Wang YM, Caldwell JH, Robertson LW, Donnerberg RL, Reuning RH. Digoxin disposition in elderly humans with hypochlorhydria. J Clin Pharmacol 1994; 34:734-41. [PMID: 7929867 DOI: 10.1002/j.1552-4604.1994.tb02033.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Digoxin (D3) metabolism is partially mediated by the gastrointestinal tract via acid hydrolysis of digitoxose sugar moieties and bacterial reduction of the lactone. The hypothesis that hypochlorhydria influences digoxin disposition was tested in six normochlorhydric (NC) and four hypochlorhydric (HC) subjects. D3 tablets were administered daily for 19 to 28 days, and quantitative urine and fecal samples were collected over the last 3 days (steady state). Samples were analyzed for D3 and its extractable metabolites by fluorescence-derivatization HPLC. Excretion of D3 in urine increased from 37% of the dose in NC to 46% in HC, whereas excretion of D3 in feces decreased from 29 to 14%. These changes were statistically significant (P < .05) and consistent with decreased hydrolysis of D3 by stomach acid and increased intestinal metabolism in HC. In each subject, D3 was added to anaerobic cultures of both feces and jejunal fluid. Digoxin was reduced in all but two of the fecal incubates, and was not reduced in any jejunal fluid incubates. Because dihydrodigoxin (DHD3) was found in only two hypochlorhydric subjects, in vitro measures of bacterial reduction of D3 were not predictive of in vivo excretion of reduced metabolites. Sugar-hydrolyzed, reduced metabolites were not found in any subjects. It is concluded that D3 disposition is altered by hypochlorhydria, and that an understanding of the metabolic mechanisms requires further study.
Collapse
Affiliation(s)
- J Hui
- College of Pharmacy, Ohio State University, Columbus 43210
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Abstract
The development of the radioimmunoassay for digoxin by Smith and coworkers in 1969 was a landmark in digitalis therapy. Since then, the complex pharmacokinetics of digoxin have been defined. As a result, the incidence of digitalis toxicity has markedly decreased. To use the digoxin assay properly, however, the relation of this pharmacokinetic parameter to digoxin pharmacodynamics must be known and the limitations of the assay itself understood. Systolic time intervals (STI) are uniquely useful to quantitate the inotropic effect of digitalis preparations. This technique can demonstrate the onset and magnitude of the inotropic effect for both oral and intravenous digitalis administration. By defining the mathematical relation between STI and simultaneous serum digoxin concentrations following intravenous administration of 1 mg digoxin, computer simulations can be made of the effect of dosing changes on blood and tissue concentrations. The serum digoxin assay has technical problems relating to quality control, interference by metabolites, and cross-reactions with endogenous digitalis-like substances. Further, a standard time for measurement following dosing has not been established. Physical activity can significantly after the serum digoxin concentrations by increasing skeletal muscle binding. Numerous drugs can interfere with digoxin absorption or elimination. Using the serum digoxin assay is the only way to assess these interactions. Computer surveillance (ideally with physician or pharmacist interaction) has been used to monitor digitalis but has not yet gained widespread acceptance. This is clearly a method in need of further testing.
Collapse
Affiliation(s)
- R P Lewis
- Division of Cardiology, Ohio State University, Columbus 43210
| |
Collapse
|
9
|
THOMAS RICHARD, GRAY PETER, ANDREWS JOANNE. Digitalis: Its Mode of Action, Receptor, and Structure–Activity Relationships. ACTA ACUST UNITED AC 1990. [DOI: 10.1016/b978-0-12-013319-2.50009-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/08/2023]
|
10
|
Sanders MR, Kostis JB, Frishman WH. The use of inotropic agents in acute and chronic congestive heart failure. Med Clin North Am 1989; 73:283-314. [PMID: 2645478 DOI: 10.1016/s0025-7125(16)30674-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
This article reviews our current understanding of the physiology of myocardial contraction; recent research into its mechanical, macromolecular, and biochemical foundations; and its role in the clinical syndromes of congestive heart failure. This review serves as a background for discussing the mechanism of action and pharmacology of currently available and experimental inotropic agents. The clinical applications of these drugs are discussed and the successes and failures of the pharmacologic approach to patients with congestive heart failure analyzed.
Collapse
Affiliation(s)
- M R Sanders
- Division of Cardiovascular Diseases and Hypertension, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick
| | | | | |
Collapse
|
11
|
Redington AN, Carvalho JS, Shinebourne EA. Does digoxin have a place in the treatment of the child with congenital heart disease? Cardiovasc Drugs Ther 1989; 3:21-4. [PMID: 2487520 DOI: 10.1007/bf01881525] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The place of digoxin in the pediatric cardiologist's armamentarium remains uncertain. As an antiarrhythmic, its use in the Wolff-Parkinson-White syndrome is obsolete, but it remains useful in the treatment of the chronic atrial fibrillation seen in some patients postoperatively and in children with dilated cardiomyopathy. The efficacy of digoxin in heart failure is unproven. There is some evidence of improvement in non invasive left ventricular contractile indices in neonates and infants, but it is unclear whether this is associated with sustained clinical improvement. There is even less evidence of its effectiveness in the older child. Whilst the measurement of any effect will undoubtedly be difficult, the time has come for double-blind, placebo-controlled trials in selected groups of patients. These should be designed not only to test the notion that digoxin does not improve ventricular function, but also to embrace the possibility that its administration may result in clinical improvement over and above that following diuretics alone. An absence of proof of efficacy must be distinguished from no efficacy--more data are needed.
Collapse
Affiliation(s)
- A N Redington
- Department of Paediatric Cardiology, Brompton Hospital, London, United Kingdom
| | | | | |
Collapse
|
12
|
Abstract
The foregoing discussion leads to several general conclusions regarding the use of digoxin in the pediatric patient. First, pharmacokinetic studies indicate that somewhat higher doses are required in the infant to attain the same serum levels as in the adult. Important sources for this difference appear to be more rapid body clearance of digoxin and larger volume of distribution in the infant. Second, higher serum digoxin levels are not indicated on the basis of decreased myocardial uptake of digoxin in the infant. Tissue uptake of digoxin, as indicated by myocardium/serum digoxin ratios, is higher in infants and children than in adults. Third, according to results of animal studies, the inotropic sensitivity to digoxin in the young is probably greater--certainly not less--than in the adult. This is opposite to a commonly held view that the immature heart is less sensitive to cardiac glycosides and therefore requires higher serum levels for a therapeutic effect. Rather, the infant has decreased sensitivity of the conduction system to digitalis toxicity, and healthy myocardium less prone to arrhythmia than the adult. Therefore the infant may tolerate, but does not require, higher serum levels of digoxin. Fourth, high levels of serum digoxin (greater than 2 ng/ml) are not associated with greater inotropic effects in the pediatric patient. The higher dosages of digoxin are, instead, associated with greater frequency of toxic effects, especially in infants receiving concomitant diuretic therapy. Therefore, a digoxin dosage recommendation is presented, that will result in mean serum digoxin levels of 1.1 to 1.7 ng/ml.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
|
13
|
Abstract
Serum digoxin assay is a useful clinical tool in monitoring the administration of digoxin. Its value, however, is generally overrated; judicious use of it applies only to specific clinical problems. Its primary use involves assay values at the two ends of the scale: low ranges may help detect noncompliant patients or those with serious absorption difficulties. Higher ranges are helpful in the clinical recognition of digitalis toxicity.
Collapse
|
14
|
Abstract
Digoxin, the cardiac glycoside most frequently used in clinical practice in the United States, can be given orally or intravenously and has an excretory half-life of 36 to 48 hours in patients with serum creatinine and blood urea nitrogen values in the normal range. Since the drug is excreted predominantly by the kidney, the half-life is prolonged progressively with diminishing renal function, reaching about 5 days on average in patients who are essentially anephric. Serum protein binding of digoxin is only about 20%, and differs markedly in this regard from that of digitoxin, which is 97% bound by serum albumin at usual therapeutic levels. Digitoxin is nearly completely absorbed from the normal gastrointestinal tract and has a half-life averaging 5 to 6 days in patients receiving usual doses irrespective of renal function. The bioavailability of digoxin is appreciably less than that of digitoxin, averaging about two-thirds to three-fourths of the equivalent dose given intravenously in the case of currently available tablet formulations. Recent studies have shown that gut flora of about 10% of patients reduce digoxin to a less bioactive dihydro derivative. This process is sensitive to antibiotic administration, creating the potential for important interactions among drugs. Serum or plasma concentrations of digitalis glycosides can be measured by radioimmunoassay methods that are now widely available, but knowledge of serum levels does not substitute for a sound working knowledge of the clinical pharmacology of the preparation used and careful patient follow-up.
Collapse
|
15
|
Smith TW, Antman EM, Friedman PL, Blatt CM, Marsh JD. Digitalis glycosides: mechanisms and manifestations of toxicity. Part III. Prog Cardiovasc Dis 1984; 27:21-56. [PMID: 6146162 DOI: 10.1016/0033-0620(84)90018-5] [Citation(s) in RCA: 62] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
16
|
Smith TW, Antman EM, Friedman PL, Blatt CM, Marsh JD. Digitalis glycosides: mechanisms and manifestations of toxicity. Part II. Prog Cardiovasc Dis 1984; 26:495-540. [PMID: 6326196 DOI: 10.1016/0033-0620(84)90014-8] [Citation(s) in RCA: 64] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
17
|
Smith TW, Antman EM, Friedman PL, Blatt CM, Marsh JD. Digitalis glycosides: mechanisms and manifestations of toxicity. Part I. Prog Cardiovasc Dis 1984; 26:413-58. [PMID: 6371896 DOI: 10.1016/0033-0620(84)90012-4] [Citation(s) in RCA: 94] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
18
|
|
19
|
Magnusson JO, Bergdahl B, Bogentoft C, Jonsson UE, Tekenbergs L. Excretion of digoxin and its metabolites in urine after a single oral dose in healthy subjects. Biopharm Drug Dispos 1982; 3:211-8. [PMID: 7139062 DOI: 10.1002/bdd.2510030304] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
The 3-day urinary excretion of digoxin, its conjugated and unconjugated hydrolytic metabolites and dihydrodigoxin, was studied in 8 healthy men after oral administration of tritiated digoxin. Analysis was performed by high pressure liquid chromatography (HPLC). The total radioactivity corresponded to 45.4 +/- 2.0 per cent (mean +/- S.E.M.) of the dose. By HPLC 42.4 +/- 2.7 per cent was recovered before and 44.0 +/- 2.7 per cent after deconjugation of the samples. Digoxin and dihydrodigoxin constituted 40.3 +/- 2.9 per cent; of this 0.7 +/- 0.4 per cent was dihydrodigoxin. The sum of the hydrolytic metabolites was 2.1 +/- 0.3 per cent before and 3.4 +/- 0.5 per cent after deconjugation. No correlation was found between gastric pH and the production of hydrolytic metabolites. The relative amount of these metabolites was maximal (mean 13.4 per cent of the excretion) in the 4-8 h sampling period. During the first 8 h an average of 8.6 per cent of the radioactivity was not recovered by HPLC. The metabolism of digoxin as judged by urinary excretion was limited and showed great variation during the early hours after treatment. The excretion of unchanged digoxin in some individuals constituted as little as 60 per cent over the first 12 h after dosing.
Collapse
|
20
|
Abstract
The urinary excretion of the relatively cardioinactive reduced metabolites of digoxin, dihydrodigoxin and related compounds was measured by radioimmunoassay in 131 normal subjects during studies of the bioavailability of digoxin preparations. Digoxin reduction products (DRP) constitute more than 5 percent of the excretion of digoxin and its metabolites in one-third of the volunteers after the administration of single or multiple doses of digoxin. There was little or no output of DRP during the first 8 hours after a single dose, with maximal excretion usually occurring on the second day. Most subjects who excreted more than 5 percent DRP on one occasion did so with each subsequent exposure to digoxin. Six volunteers, however, in whom substantial amounts of DRP had previously been found, failed to excrete detectable quantities after subsequent doses. In two, this change occurred shortly after they took erythromycin. Urinary DRP were less after the intravenous administration compared to the oral administration of digoxin. After oral doses, DRP excretion tended to vary inversely with the bioavailability of the preparation. The findings are consistent with the hypothesis that DRP are formed as the result of the activity of a variable component of the intestinal flora. Prospective studies will be necessary to prove this hypothesis.
Collapse
|
21
|
Jogestrand T, Ericsson F, Sundqvist K. Skeletal muscle digoxin concentration during digitalization and during withdrawal of digoxin treatment. Eur J Clin Pharmacol 1981; 19:97-105. [PMID: 7202477 DOI: 10.1007/bf00568395] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Blood samples and skeletal muscle biopsies (m. quadriceps femoris, vastus lateralis) were taken from 15 patients during digitalization or during withdrawal of digoxin treatment for analysis of serum and skeletal muscle digoxin concentrations. A percutaneous needle biopsy technique was used for muscle sampling and digoxin was analysed by radioimmunoassay. During "slow" digitalization with 0.25 mg digoxin daily the skeletal muscle digoxin concentrations after 2 and 4 days were 45% (range 19%--62%; n = 3) and 78% (range 56%--92%; n= 3) respectively, of the steady state concentration (defined as the digoxin concentration after 25--40 days of treatment). After 9 and 11 days of treatment the skeletal muscle digoxin concentrations were 106% (range 84%--133%; n = 5) and 116% (range 72%--164%; n = 3) respectively, of the steady state concentration. A doubling of the digoxin dose gave a proportional increase in skeletal muscle digoxin concentration (three patients). The magnitude of the estimated half-life of skeletal muscle digoxin was the same as previously reportedly in healthy subjects. No significant correlations were found between changes in systolic time intervals and steady state serum or skeletal muscle digoxin concentrations.
Collapse
|
22
|
|
23
|
Abstract
The pharmacokinetics and pharmacodynamics of digoxin in premature infants was studied. During maintenance therapy, after a total digitalizing dose of 30 microgram/kg, the measured digoxin level was related inversely to body weight at birth and to estimated gestational age. The serum digoxin levels found in the immature and smaller infants were two to three times the values usually reported to be toxic in older children. Based on these findings, a second group of premature infants was digitalized with 20 microgram/kg; in this group, the serum digoxin levels were below the toxic range, irrespective of gestational age or birth weight. The cardiac effects of digoxin, i.e., shortened left ventricular pre-ejection period and ejection time as determined by echocardiography, were similar in the two groups. For both groups, the half-life of digoxin in the serum was twice that reported for term infants and children. Since digitalis effect is obtained with lower dose and serum concentration, we recommend that this dose be used in premature infants.
Collapse
|
24
|
Tsutsumi E, Fujiki H, Takeda H, Fukushima H. Effect of furosemide on serum clearance and renal excretion of digoxin. J Clin Pharmacol 1979; 19:200-4. [PMID: 438354 DOI: 10.1002/j.1552-4604.1979.tb01652.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Serum turnover and urinary excretion of digoxin with or without oral furosemide were studied in six healthy subjects who received 0.006 mg/kg body weight digoxin intravenously. During furosemide treatment, the total amount of urinary digoxin did not change but the digoxin clearance during the diuretic phase and the digoxin excretion after the diuresis decreased significantly. The average serum half-life was prolonged from 37 hours in the control period to 86 hours in the furosemide period. Decreased glomerular filtration rate by volume depletion might have been responsible for the decreased excretion of digoxin, but there was no significant difference in urine volume after diuresis between the two periods, suggesting the possibility of inhibition of tubular secretion of digoxin by furosemide. It is also possible that serum digoxin concentration may be elevated if furosemide were given more frequently.
Collapse
|
25
|
|
26
|
Masson JP, Bass O, Baur HR, Ohnhaus EE. [The pharmacokinetics of digoxin during chronic spironolacton treatment (author's transl)]. KLINISCHE WOCHENSCHRIFT 1978; 56:1071-6. [PMID: 713428 DOI: 10.1007/bf01476555] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
27
|
Shapiro W. Current considerations in digoxin usage. CRC CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES 1978; 9:321-46. [PMID: 401374 DOI: 10.3109/10408367809150924] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Basic considerations in biotransformation and pharmacodynamics are presented as a basis for understanding clinical usage. The role of polarity in determining a given glycoside's duration of action and extent of biotransformation is emphasized. The pharmacokinetics are summarized emphasizing the fact that digoxin is not completely absorbed by oral administration. The important relationship of serum digoxin levels to myocardial content and apparently to myocardial response is reviewed. This relationship and the development of precise methods for measurement of digoxin in serum provide the clinician with accurate means to assess myocardial tolerance for digoxin under diverse clinical circumstances. This review includes discussion of methods of digitalization, appropriate use of serum levels, apparent and real resistance to digoxin, and apparent and real sensitivity to digoxin. The limitations of serum levels as a precise guide to toxicity are analyzed. Finally, new developments in use of immunologic therapy for digoxin intoxication are presented.
Collapse
Affiliation(s)
- W Shapiro
- Dallas Veterans Administration Hospital, Texas
| |
Collapse
|
28
|
Colaizzi JL. Digoxin. JOURNAL OF THE AMERICAN PHARMACEUTICAL ASSOCIATION 1977; 17:635-8. [PMID: 908820 DOI: 10.1016/s0003-0465(16)34485-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
29
|
Marinow J, Olcay A, Schaumann W, Weiss W. Serum glycoside concentrations after single or repeated intravenous doses of beta-methyl-digoxin and digoxin. Eur J Clin Pharmacol 1977; 11:213-8. [PMID: 856604 DOI: 10.1007/bf00606413] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
The aim of the present investigation was to estimate the ratio of the intravenous doses of beta-methyl-digoxin and digoxin required to produce identical serum glycoside concentrations in man. 20 patients on intravenous maintenance therapy were changed from beta-methyl-digoxin to the identical dose of digoxin or vice versa. Each drug was given for 7 days. Serum concentrations 13% higher were found during administraton of beta-methyl-digoxin. Assuming a half life of 60 h after withdrawal, the dose of digoxin producing the same minimum serum concentration was estimated to be 1.16 times higher than that of beta-methyl-digoxin. 18 healthy volunteers received 0.4 mg beta-methyl- digoxin, and 23 the same dose of digoxin, as an intravenous infusion over 2 h. The serum concentrations and urinary glycoside excretion were measured over a period of 32 hrs. During the first hour after the infusion the serum concentration of digoxin declined more rapidly than that of beeta-methyl-digoxin. Thereafter, the ratio of the serum concentrtions did not change appreciably up to the end of the investigation. The area under the serum concentration/time curve was about 13% greater for beta-methyl-digoxin than for digoxin; this difference was not significant. The average renal clearance was 96 +- 9 ml for beta-methyl-digoxin, 151 +- 13 ml for digoxin. Since the total body clearance of digoxin is only about 1.16 times higher than that of beta-methyl-digoxin, the lower renal clearance of beta-methyl-digoxin must partly be compensated by higher extrarenal clearance. From the ratios of the areas under the serum concentration/time curves after single doses of beta-methyl-digoxin and digoxin, and the minimum serum concentrations during maintenance therapy, it was concluded that the dose of digoxin to produce the same average serum concentrations would be about 1.15 times higher than that of beta-methyl-dogoxin. In comparison wtih the large variations in individual dosage of digoxin and beta-methyl-digoxin, this difference is too small to be of practical importance.
Collapse
|
30
|
Kramer P. Digitalis pharmacokinetics and therapy with respect to impaired renal function. KLINISCHE WOCHENSCHRIFT 1977; 55:1-11. [PMID: 319291 DOI: 10.1007/bf01469777] [Citation(s) in RCA: 30] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The various cardiac glycosides differ significantly in their retention as a result of renal failure. In the case of digoxin, digitoxin, and strophanthin the retention is directly related to the normal renal clearance of these cardiac glycosides: Strophanthin has the highest clearance and the most marked prolongation of pharmacological action in renal failure, whereas digitoxin shows the lowest renal clearance and even in uremic patients a total elimination comparable to normal subjects as a result of increased hepatic clearance; digoxin takes an intermediate position. The quantity of a cardiac glycoside and its metabolites excreted by the kidneys depends, besides the renal clearance, on the plasma concentration which increases considerably during the first days after onset of treatment. From the daily dose approximately 90% of strophanthin, 70% of digoxin, 50% of digitoxin plus metabolites are excreted by normal kidneys under steady-state conditions. The efficiency of hemodialysis in the elimination of cardiac glycosides is low (3-5%) if estimated in relation to a single dose injected before dialysis and high (30-50%) if estimated in relation to the excretory capacity of normal kidneys during a period corresponding to the duration of a dialysis. During hemodialysis the plasma concentration of digoxin decreases as rapidly as in patients with normal renal function. Beside the efficiency of dialysis this finding may be explained by the decrease in the apparent volume of distribution of cardiac glycosides in patients with advanced renal failure; a reduced tissue protein binding seems likely to be the main reason for these changes in chronic renal insufficiency. A reduced volume of distribution and a reduced myocardial sensitivity are the main reasons for a very low predictability of the necessary individual maintenance dose of cardiac glycosides from the creatinine clearance. In patients with advanced renal insufficiency the tolerance to cardiac glycosides is reduced with respect to the daily dose, but it is rather increased in relation to the plasma concentration required to maintain the positive inotropic effect. The combination of hyperkalemia, hypermagnesemia, bypocalcemia and acidosis which is found almost exclusively with chronic renal failure, may explain the reduced myocardial sensitivity. Dosage regimens based on the measurement of creatinine-clearance are of little help in "effective digitalisation". Serial measurements of steady-state plasma concentration of cardiac glycosides may be the only way to reduce the risk of under- and overtreatment in patients with impaired renal function.
Collapse
|
31
|
Abstract
Predictable hydrolysis of [3H]digoxin-12alpha occurred in vitro with incubation in HCl or gastric juice. Hydrolysis varied with pH, time, temperature and agitation. Digoxin, the bis- and mono-digitoxosides of digoxigenin and digoxigenin were separated by silica gel thin-layer chromatography using chloroform-ethyl acetate-glacial acetic acid (25:25:1 v/v) and were quantitated by liquid scintillation spectrometry. Hydrolysis with incubation at 37 degrees and pH 3 for 90 min was minimal, but increased with increasing acidity until greater than 70% was hydrolysed at pH 1-2 after 30 min and greater than 96% after 90 min incubation. At pH 0-9, 87% was hydrolysed after 30 min. In vitro hydrolysis in gastric fluid was slightly less than in HCl at the same pH. A volunteer was given 150 muCi[3H]digoxin-12alpha by nasogastric tube during a pentagastrin infusion when gastric pH was 0-94. He remained on his left side and samples were aspirated at intervals and immediately neutralized. Ethanol-chloroform 50-50 (v/v) extracts of the gastric fluid aspirated after 90 min and of all the urine specimens collected for 5 days were applied to a DEAE Sephadex LH-20 column. The radioactivity appeared in a single peak as digoxigenin in the 90 min gastric aspirate and in all urine specimens. Extensive intragastric hydrolysis of digoxin may occur under conditions of maximum acid output.
Collapse
|
32
|
Marzo A, Ghirardi P, Riva O, Maggi GC, Scalvini A, Marchetti G. Plasma turnover and excretion of K-strophanthoside-3H in human volunteers after parenteral administration. NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY 1976; 294:115-20. [PMID: 1012332 DOI: 10.1007/bf00507843] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Pharmacokinetic parameters of K-strophanthoside-3H, a short-acting cardiac glycoside, were investigated in healthy subjects, patients suffering from heart disease, renal failure and in cholecystectomized patients with a biliary T-tube inserted surgically, after parenteral administration of 250 mug of the glycoside. The healthy subjects, patients suffering from heart disease and those with the biliary T-tube showed a dominant half-time for plasma turnover of the glycoside of 15-16 h after the i.v. route and 18-22 h after the i.m. route and cumulative urinary excretion of the drug over a 24 h period of 37-42% (i.v. route) and 32-33% (i.m. route). The volumes of distribution were lower in patients with heart disease and patients with biliary fistula than in the healthy subjects. In patients suffering from renal failure the dominant half-time of plasma turnover was higher (33 h), while cumulative urinary excretion of the glycoside (12%) and the volumes of distribution were lower than in the healthy subjects. A peak of plasma levels 30 min after i.m. administration of K-strophanthoside-3H leads to the conclusion that this glycoside is rapidly absorbed when injected intramuscularly.
Collapse
|
33
|
Storstein L. Studies on digitalis. IV. A method for thin-layer chromatographic separation and determination of digitoxin and cardioactive metabolites in human blood and urine. J Chromatogr A 1976; 117:87-96. [PMID: 175079 DOI: 10.1016/s0021-9673(00)81069-9] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
A thin-layer chromatographic method for the separation of digitoxin and its cardioactive metabolites in one system is described. Pre-coated silica gel plates impregnated with 15% formamide solution in acetone were developed twice in the same direction (running distance 18cm) with ethyl methyl ketone-xylene (50:50) as solvent. The system showed no border-zone effects, and the reproducibility was good. Samples (5 ml) of serum or urine were extracted with dichloromethane, the extracts were evaporated, the residues were dissolved in 70% ethanol, the ethanol solutions were washed twice with light petroleum and then evaporated, and the residues were dissolved in chloroform-methanol for application to the thin-layer plates. After development, the metabolites were scraped from the plates and analyzed by means of a modified rubidium-86 method. The recovery for the whole procedure was 59%, and the sensitivity of the method permitted the determination of down to 0.5 ng per spot. The method will facilitate the study of digitoxin metabolism in patients undergoing treatment with the drug.
Collapse
|
34
|
Teske RH, Bishop SP, Righter HF, Detweiler DK. Subacute digoxin toxicosis in the beagle dog. Toxicol Appl Pharmacol 1976; 35:283-301. [PMID: 1265746 DOI: 10.1016/0041-008x(76)90288-x] [Citation(s) in RCA: 41] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
35
|
|
36
|
Abstract
1. Elimination rates of tritiated ouabain, digoxin and digitoxin after single intravenous administrations were investigated in guinea-pigs, the total radioactivity in whole blood being traced for a period of up to 2 weeks. 2. In the initial rapid phase of elimination between 2 and 30 min following intravenous glycoside administration, the concentration decline of radioactivity in the blood was found to be identical for the three glycosides investigated, this part of the elimination curve displaying a hyperbolic shape. 3. During this early elimination phase, rapid metabolic degradation and excretion of digoxin had already taken place. The maximum concentration of radioactivity in the bile was reached 4 min following intravenous administration of 3H-digoxin. The positive inotropic response occurred in the cat heart-lung preparation 1.5 min after intravenous injection of a therapeutic dose of digoxin, indicating a quick occupation of binding sites in the tissues. 4. The biological half-lives of tritiated ouabain, digoxin and digitoxin averaged 11 h, 2.5 days and 4.1 days, respectively, as determined by the terminal exponential elimination phase, in guinea-pigs. This terminal phase was attained 6-12, 7-24, and 24-48 h after administration of ouabain, digoxin and digitoxin, respectively. 5. The findings reveal that in guinea-pig, as has been demonstrated in man, the elimination rates of the three glycosides increase according to their hydrophobic properties. 6. The biological half-lives of tritiated ouabain, digoxin and digitoxin obtained in the guinea-pig closely resemble those found in healthy man.
Collapse
|
37
|
Ochs H, Bodem G, Hahn E, Dengler HJ. [Comparison of digitoxin bioavailability from tablets and elixir during maintenance therapy (author's transl)]. KLINISCHE WOCHENSCHRIFT 1975; 53:425-9. [PMID: 1152354 DOI: 10.1007/bf01493367] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
The bioavalability of digoxin tablets and solution has been studied during maintenance therapy in a cross over study. Each preparation was given over a period of at least 7 days to patients with compensated congestive heart failure. Urine concentrations and plasma levels were analysed for digitoxin. There was no significant difference between the two preparations. Determination of steady state serum concentrations and urinary excretion during maintenance therapy as an index of bioavalability are more cumbersome than a single dose study. From a pharmacokinetic point of view however, analyses of steady-state conditions are preferable to a single dose study. In addition, steady state of drug input and output resembles the usual digitalis therapy.
Collapse
|
38
|
|
39
|
Hoeschen RJ, Cuddy TE. Dose-response relation between therapeutic levels of serum digoxin and systolic time intervals. Am J Cardiol 1975; 35:469-72. [PMID: 1119396 DOI: 10.1016/0002-9149(75)90828-0] [Citation(s) in RCA: 53] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
A dose-response relation between cardiac glycosides and systolic time intervals has previously been established in short-term studies in which the glycoside was administered intravenously in these studies there was uncertainty regarding the steady state kinetics, and maintenance of the early serum levels would have resulted in toxicity. Accordingly, we studied the effect on systolic time intervals of small increments of serum digoxin within the therapeutic range. Serum digoxin concentration and systolic time intervals were measured in 21 patients receiving 0.25 mg of the glycoside daily. The daily dose was increased to 0.5 mg and measurements were repeated 5 to 7 days later. Serum digoxin concentration with the smaller dose was 0.56 plus or minus (standard error) 0.06 ng/ml and increased to 1.18 plus or minus 0.11 ng/ml with the larger dose. Associated with the increased serum digoxin was a mean decrease in duration of total electromechanical events of 6.3 plus or minus 2.9 msec (P smaller than 0.025), which resulted from a mean shortening of left ventricular ejection time of 5.6 plus or minus 3.0 msec (P smaller than 0.05). The mean decrease in preejection phase of 1.1 plus or minus 2.1 msec was insignificant (P larger than 0.2). Repeated measurements in control patients showed no change in serum digoxin concentration or systolic time intervals. In nine patients the digoxin dose was randomly varied between 0 and 0.75 mg and measurements were made 4 to 5 days after drug administration at each dose level. The correlation coefficient between changes in serum digoxin and changes in left ventricular ejection time was minus 0.55 (P smaller than 0.01) the data indicated that increasing the maintenance dose of digoxin while keeping the serum level within therapeutic range will result in improved ventricular function as assessed by determination of systolic time intervals.
Collapse
|
40
|
Abstract
The pharmacokinetics of the cardiac glycofides have been elucidated as a result of the development of assays of sufficient sensitivity to measure the concentration of digitalis compounds in biological fluids. Digoxin can accumulate in the body without the administration of a loading dose, and a steady state blood concentration will be reached in 5 to 7 days. Digitoxin requires 35 days to accumulate to a plateau. If a loading dose of digoxin is used, it should be approximately three times the estimated daily maintenance dose. Factors that determine the selection of the appropriate maintenance dose of digoxin include renal function and lean body mass. Digitoxin is less dependent on renal function for its elimination than is digoxin. Knowledge of the pharmacokinetics of digitalis preparations is useful in determining how to change from one cardiac glycoside to another, each with different half-lives. One should wait 3 days before starting digoxin therapy when changing from maintenance digitoxin to digoxin (assuming normal renal function). The pharmacokinetics of changing from ouabain to digoxin without loss of digitalis effect are described. The metabolism of the commonly used digitalis preparations are summarized.
Collapse
|
41
|
Moss AJ, Finkelstein S, Crudup C, Young GA, Dooley RR, Osher AB. Absorption of digoxin in children with cystic fibrosis. J Pediatr 1975; 86:295-7. [PMID: 1111698 DOI: 10.1016/s0022-3476(75)80493-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
The absorption of digoxin in cystic fibrosis was evaluated in 16 subjects by assessing the relationship between dosage expressed in mug/kg/day and serum digoxin concentration. The results indicate that the same relationship exists between maintenance dosage and serum levels in these patients and in patients without cystic fibrosis. Thus, no evidence of impaired absorption was found.
Collapse
|
42
|
Kramer WG, Lewis RP, Cobb TC, Forester WF, Visconti JA, Wanke LA, Boxenbaum HG, Reuning RH. Pharmacokinetics of digoxin: comparison of a two- and a three-compartment model in man. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS 1974; 2:299-312. [PMID: 4449007 DOI: 10.1007/bf01061404] [Citation(s) in RCA: 67] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|
43
|
|
44
|
|
45
|
Shaw TR, Howard MR, Hamer J. Recent changes in biological availability of digoxin. Effect of an alteration in 'Lanoxin' tablets. BRITISH HEART JOURNAL 1974; 36:85-9. [PMID: 4818143 PMCID: PMC1020015 DOI: 10.1136/hrt.36.1.85] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
46
|
Abshagen U, Rennekamp H, Küchler R, Rietbrock N. Formation and disposition of bis- and monoglycosides after administration of 3H-4'''-methyldigoxin to man. Eur J Clin Pharmacol 1974; 7:177-81. [PMID: 4852077 DOI: 10.1007/bf00560378] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
47
|
|
48
|
Falch D. The influence of kidney function, body size and age on plasma concentration and urinary excretion of digoxin. ACTA MEDICA SCANDINAVICA 1973; 194:251-6. [PMID: 4749161 DOI: 10.1111/j.0954-6820.1973.tb19442.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
49
|
|
50
|
|